Evidence map›Paper›PMID 40283397›Full record

ArticleJournal of clinical medicine2025

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β

Toru Oga, Yasuhiro Gon, Masashi Takano, Risako Ito, Chifuku Mita, Isao Mukai, Stephen G Noorduyn, Gema Requena, Masao Yarita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toru OgaDepartment of Respiratory Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Yasuhiro GonDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Toyko 173-8610, Japan.ORCID 0000-0003-0514-3054
Masashi TakanoReal World Data Analytics, Japan Development, GSK, Tokyo 107-0052, Japan.ORCID 0000-0002-4625-3762
Risako ItoValue Evidence and Outcomes, Chief Patient Officer Organization, GSK, Tokyo 107-0052, Japan.ORCID 0009-0006-6820-0561
Chifuku MitaReal World Data Analytics, Japan Development, GSK, Tokyo 107-0052, Japan.ORCID 0009-0000-0510-8641
Isao MukaiRespiratory Medical Affairs, Japan Medical Affairs, GSK, Tokyo 107-0052, Japan.
Stephen G NoorduynReal World Evidence and Health Outcomes, Global Medical, GSK, Mississauga, ON L5R 4H1, Canada.ORCID 0000-0002-5936-5579
Gema RequenaGlobal Value Evidence and Outcomes, Epidemiology, GSK, London WC1A 1DG, UK.
Masao YaritaReal World Data Analytics, Japan Development, GSK, Tokyo 107-0052, Japan.ORCID 0000-0001-5770-4496

Funding

GSK study 217515
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adrenergic β2 receptor agonistanti-asthmatic agentsasthma exacerbationcorticosteroidfluticasone furoate/umeclidinium/vilanterolJapansingle-inhaler triple therapy

Identifiers

PMID40283397
PMCPMC12028120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.